Compare Ginkgo Bioworks Holdings Inc (DNA) vs Williams Companies Inc (WMB) Price & Performance

Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.

DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.

Williams Companies (WMB) trades at $71.85, up 2.06% today, with a neutral technical signal and mixed earnings history. The company reported Q2 2026 EPS of $0.50, slightly missing estimates, but raised full-year EBITDA guidance. Recent news highlights the $5.5 billion acquisition of Momentum Midstream, enhancing its Gulf Coast presence and supporting long-term growth targets. Financials show strong profitability with a 25.18% net income margin and robust cash flow from operations of $5.90 billion in 2025.

Outlook remains positive with analyst consensus favoring Buy ratings (79.41%) and a $87.14 price target, though risks include execution of acquisitions and debt levels. The stock offers a dividend yield supported by stable cash flows, positioning it for growth in energy infrastructure demand.